Cabaletta Bio Inc CABA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-10-25 |
| Shares Out. | 163,050,000 |
| Website | cabalettabio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 158 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$51.0M |
| Free Cash Flow | -$154.2M |
| Total Assets | $256.7M |
| Total Liabilities | $46.1M |
| Equity | $210.6M |
About Cabaletta Bio Inc
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Cabaletta Bio Inc is a publicly traded company under the ticker symbol CABA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)